益盛藥業(002566.SZ):擬與中娛數媒共同投資設立益盛新零售(杭州)
格隆匯 10 月 20日丨益盛藥業(002566.SZ)公佈,2020年10月16日,吉林省集安益盛藥業股份有限公司發佈了《關於與杭州錢塘智慧城管理委員會簽訂戰略合作框架協議的公告》。根據戰略合作框架協議的內容,為加快益盛新零售項目的落地和發展,公司擬與中娛數媒文化發展(杭州)有限公司(“中娛數媒”)共同投資設立控股子公司“益盛新零售(杭州)有限公司”(暫定名稱,最終以工商行政管理機關核准的名稱為準)。其中,益盛藥業出資510萬元,佔註冊資本的51%;中娛數媒出資490萬元,佔註冊資本的49%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.